Alto Neuroscience, Inc.

For the period ended Dec 31, 2025. Filed Mar 16, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 16, 2026

ANRO$27.80+10.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except per share amounts)

	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$176,484	$168,229
Prepaid expenses and other current assets	1,234	1,108
Total current assets	177,718	169,337
Restricted cash	500	500
Property and equipment, net	1,872	2,666
Operating right-of-use asset	4,261	5,035
Other assets	338	4
Total assets	$184,689	$177,542
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$1,878	$1,579
Accrued expenses and other current liabilities	8,862	8,429
Term loan, current	585	—
Total current liabilities	11,325	10,008
Term loan, non-current	16,172	10,254
Convertible Grant Agreement	2,227	1,304
Lease liability, long-term	3,823	4,516
Total liabilities	33,547	26,082
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock (par value $0.0001), 500,000 shares authorized; 31,924 and 26,987 shares issued and outstanding as of December 31, 2025 and 2024	3	3
Additional paid-in capital	352,751	289,954
Accumulated deficit	(201,634)	(138,396)
Accumulated other comprehensive loss	22	(101)
Total stockholders’ equity	151,142	151,460
Total liabilities and stockholders’ equity	$184,689	$177,542

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.